Clinical studies show that 68Ga-labeled affibody molecules enable high-contrast imaging of HER2 expression in tumors, can discriminate between breast cancer metastases with high and low HER2 expression, are nontoxic and nonimmunogenic, and inflict a low absorbed dose burden in patients [14, 15]. The gene discussed is ERBB2; the disease is breast carcinoma.